Novel composition-of-matter patent supports formulation innovation as development advances and patient access expand CHICAGO — April 9, 2026 —Emalex Biosciences today announced that the U.S. Patent and Trademark Office issued a patent covering an orally disintegrating tablet (ODT) formulation of ecopipam, an investigational D1 receptor … Read more
– Study data shows investigational new drug, ecopipam, reduced total number of tics by 30% compared to placebo – CHICAGO—January 11, 2023 – A Phase 2b clinical trial involving more than 150 children and adolescents with Tourette syndrome found ecopipam significantly reduced the total number of … Read more
– Findings show investigational drug reduces tics by 30%; Data presentation April 5 – Chicago, March 31, 2022 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) movement disorders and fluency disorders, will present an abstract — … Read more
– License agreement secures potential research of ecopipam for one of the most common neurological sensory disorders – Chicago, March 1, 2022 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) movement disorders and fluency disorders, today … Read more
– Statistically significant, clinically meaningful results obtained on the primary and multiple secondary efficacy endpoints; ecopipam well tolerated in the study – Chicago, Nov. 10, 2021 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company founded by Paragon Biosciences to develop treatments for central nervous system … Read more